Nfkb2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NFKB2 encodes the p100 (NFKB2) protein, which is a member of the NF-κB transcription factor family. Unlike other NF-κB proteins, NFKB2 is synthesized as a full-length p100 that functions as both an inhibitor and a transcription factor. The p100 precursor can be proteolytically processed to generate the active p52 subunit, which translocates to the nucleus. NFKB2 is crucial for immune function, inflammation, and cell survival. Germline mutations in NFKB2 cause immunodeficiency and endocrine disorders [1][2].
| Attribute |
Value |
| Gene Symbol |
NFKB2 |
| Full Name |
Nuclear Factor Kappa B Subunit 2 |
| Chromosomal Location |
10q24.32 |
| NCBI Gene ID |
4791 |
| Ensembl ID |
ENSG00000100908 |
| UniProt ID |
Q12986 |
| Aliases |
p100, LYT10, NF-κB2 |
NFKB2 spans ~15 kb:
- Exons: 24 coding exons
- Transcript: ~2.8 kb mRNA
- Protein: 900 amino acids, ~100 kDa (p100); 52 kDa (p52)
NFKB2 regulates:
- Non-canonical pathway — Specific NF-κB signaling
- B cell function — Maturation and survival
- Lymphoid organogenesis — Secondary lymphoid structures
- Adaptive immunity — T cell dependent responses
p100 to p52:
- Constitutive processing — Basal levels
- Inducible processing — Via NIK kinase
- Signal-specific — Lymphoid receptor signaling
- Dimer formation — With RelB for active complex
NFKB2 regulates:
- Immune genes — Cytokines, chemokines
- Survival genes — Bcl-2 family
- Differentiation — Cell fate genes [^3]
NFKB2 in AD:
- Neuroinflammation — Elevated p100/p52 in AD
- Aβ response — Activated by amyloid
- Neuronal dysfunction — Altered NF-κB regulation
- Neuroinflammation — p52 pathway activated in PD
- Dopaminergic neurons — May affect survival
- Ischemic injury — p100 processing after stroke
- PMID:8340146 — Discovery of NFKB2
- PMID:10625657 — NFKB2 structure
- PMID:11025718 — Non-canonical NF-κB
- PMID:21479819 — NFKB2 in neurodegeneration
The study of Nfkb2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
NFKB2 exhibits tissue-specific expression:
- Immune system: High expression in spleen, thymus, lymph nodes
- Brain: Detected in neurons, astrocytes, and microglia
- Peripheral tissues: Moderate expression in lung, liver, kidney
- Cell lines: Various leukemia and lymphoma cell lines
In the brain:
- Neurons: Constitutive expression in cortical and hippocampal neurons
- Astrocytes: Upregulated during neuroinflammation
- Microglia: Strong activation-dependent expression
- Oligodendrocytes: Lower baseline expression
Nfkb2 knockout mice have provided insights:
- Defective lymphoid organogenesis: Impaired lymph node development
- B cell abnormalities: Reduced B cell numbers and function
- Humoral immunity defects: Poor antibody responses
- Partial lethality: Some embryonic lethality in null mice
- Constitutive activation: p52 overexpression models
- Brain-specific: Neuronal NFKB2 deletion studies
- Disease models: Crossed with APP/PSEN1 for AD studies
NFKB2 interacts with several proteins:
- RELB: Forms active p52/RELB heterodimer
- NFKB1 (p105): Can form heterodimers
- IKBKB: Phosphorylation target
- NIK (MAP3K14): Key kinase for processing
- BCL3: Co-activator protein
- Canonical与非canonical交叉: p100 can inhibit canonical NF-κB
- Processing machinery: Proteasome-dependent degradation
- Nuclear import: Through nuclear localization signals
NFKB2 mutations cause:
- Immunodeficiency: Combined immunodeficiency
- Endocrine disorders: ACTH deficiency
- Alopecia: Hair loss in some patients
- Autoimmunity: Lupus-like features
- Lymphomas: Mutations in B cell malignancies
- Solid tumors: Altered in some carcinomas
- Autoimmune disease: Association with autoimmune disorders
Drugs targeting NFKB2 pathway:
- NIK inhibitors: Under development for cancer
- Proteasome inhibitors: Bortezomib affects p52 processing
- Broad NF-κB inhibitors: Affects multiple pathways
NFKB2 as a biomarker:
- Disease activity: Levels correlate with inflammation
- Treatment response: Changes with therapy
- Prognostic value: In some malignancies
- NF-κB in Alzheimer's disease (2008)
- NF-κB and neuroinflammation in PD (2012)
- Microglial NF-κB activation in neurodegeneration (2015)
- Therapeutic targeting of NF-κB in AD (2019)
- α-synuclein and NF-κB activation (2014)
- NFKB2 in immune regulation (2017)